Page last updated: 2024-12-11
leucokinin i
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
leucokinin I: an eight amino acid neuropeptide found in the nervous system of the bowfly; aa sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5491285 |
| CHEBI ID | 80183 |
| MeSH ID | M0223146 |
Synonyms (13)
| Synonym |
|---|
| leucokinin i |
| 104600-89-7 |
| (3s)-3-amino-4-[(2s)-2-[[(2s)-1-[[(2s)-1-[[(2s)-4-amino-1-[[(2s)-1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-y |
| asp-pro-ala-phe-asn-ser-trp-gly-nh2 |
| leukokinin i |
| CHEBI:80183 |
| DTXSID90146608 |
| J-001201 |
| glycinamide, l-alpha-aspartyl-l-prolyl-l-alanyl-l-phenylalanyl-l-asparaginyl-l-seryl-l-tryptophyl- |
| Q27149296 |
| (s)-4-((s)-2-(((5s,8s,11s,14s,17s)-5-((1h-indol-3-yl)methyl)-1-amino-11-(2-amino-2-oxoethyl)-14-benzyl-8-(hydroxymethyl)-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazaoctadecan-17-yl)carbamoyl)pyrrolidin-1-yl)-3-amino-4-oxobutanoic acid |
| glycinamide,l-alpha-aspartyl-l-prolyl-l-alanyl-l-phenylalanyl-l-asparaginyl-l-seryl-l-tryptophyl- |
| AKOS040744659 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| peptide | Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (76.92) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||